Table 3.
Comparison of cytogenetic abnormalities and outcomes between patients with second MN after breast cancer (surgery/hormonal therapy alone) and matched de novo MN
| Characteristic | Second MN (n=42) | De novo MN (n=82) | P value |
|---|---|---|---|
| Age, years | |||
| Median (range) | 70.4 (39.5, 82.7) | 69.8 (39, 81.5) | .78 |
| WBC, × 109/L | |||
| Median (range) | 4.9 (1.2, 161.0) | 6.0 (0.5, 233.0) | .43 |
| Platelet, × 109/L | |||
| Median (range) | 60 (8, 398) | 60 (4, 606) | .41 |
| HGB, g/dL | |||
| Median (range) | 9.1 (5.0, 13.3) | 8.9 (4.0, 15.4) | .82 |
| BM blasts (%) | |||
| Median (range) | 10 (0, 93) | 17 (0, 97) | .66 |
| Performance status* | |||
| 0–1 | 31(73.8%) | 62(75.6%) | .83 |
| >1 | 11(26.2%) | 20(24.4%) | |
| Abnormal karyotype | 21(55.3% out of 38) | 31(40.8% out of 76) | .14 |
| Del(5q)/-5, del(7q)/-7, and/or complex karyotype | 7(16.7%) | 9(11%) | .37 |
| Complete remission | 15(35.7%) | 27(32.9%) | .76 |
| Median OS time (range), months | 15.6 (10.0, 32.5) | 14.7 (9.1, 17.3) | .71 |
| 5-year OS rate (range) | 18% (9%, 35%) | 18% (11%, 30%) |
MN, myeloid neoplasm; WBC, white blood cell; HGB, hemoglobin; BM, bone marrow.; OS, overall survival.
*
Eastern Cooperative Oncology Group